At SoveRIN, we discover and develop small-molecule therapeutics to address significant unmet medical needs. Our pipeline is built on deep science, clear strategic focus, and a commitment to creating meaningful value for patients.
We advance a focused pipeline of small-molecule therapeutics, addressing areas of high unmet need with a clear rationale, disciplined execution, and the potential for meaningful impact.
We are developing a novel, small-molecule therapeutic for dry eye disease, aiming to address the underlying disease mechanisms and deliver long-lasting relief.
View Program →
We apply our deep understanding of inflammatory pathways to develop small-molecule therapeutics for chronic inflammatory diseases with high unmet need.
View Program →
We are developing small-molecule therapeutics to modulate neuroinflammation and related pathways, with the goal of slowing disease progression and preserving cognitive function.
View Program →
We are exploring small-molecule approaches to target key pathways in cancer, with the aim of delivering differentiated therapeutics for patients with high unmet needs.
View Program →We are committed to advancing science with discipline and purpose, transforming innovative ideas into therapies that make a meaningful difference in patients’ lives.